GeneCast
GeneCast is a South Korea-based clinical diagnostics company founded in 2016 that develops proprietary ADPS liquid biopsy assays for early detection and mutation analysis of cancer-related genes, serving clinicians, hospitals, and reference laboratories.
- Company typePrivate
- Founded2016
- HeadquartersSongpadong, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What GeneCast does
GeneCast is a South Korean clinical diagnostics company founded in 2016 that develops liquid biopsy assays for early detection and mutation analysis of cancer-related genes using its proprietary ADPS technology. The company sells into the oncology diagnostics value chain — serving clinicians, hospitals, and reference laboratories seeking non-invasive blood-based alternatives to tissue biopsy for cancer screening, monitoring, and molecular profiling. Its product positioning spans two distinct clinical use cases: early-stage cancer detection and longitudinal mutation analysis, both delivered via a circulating tumor DNA (ctDNA) workflow enabled by its proprietary assay chemistry.
The company is privately held, headquartered in Songpadong, South Korea, and operates with 11–50 employees under a co-CEO founder-led structure (Lee Byung-chul and Baek Seung-chan) supported by a CFO (Kim Hyung-geun) and CTO (Kang Ju-il). GeneCast has raised approximately $20.8M cumulatively across multiple funding rounds between 2017 and 2024, with notable strategic participation from Green Cross Medical Science in its 2020 round, suggesting distribution alignment with a major Korean diagnostics group. The company maintains an English-language web presence (igenecast.com/eng) consistent with intent to address cross-border clinical and research customers.
Business model mechanics are not disclosed in available source material — there is no publicly available pricing model, customer count, revenue figure, or reimbursement pathway. Commercial mechanics are therefore inferred from the diagnostics industry norm of fee-for-service per assay or per test report, sold to hospitals, oncology clinics, and reference laboratories, with the Green Cross Medical Science relationship providing a likely Korean distribution channel. Revenue concentration, geography mix, and unit economics cannot be quantified from the supplied data.
GeneCast firmographics
Firmographics- Name
- GeneCast
- Website
- https://genecast.co.kr
- Company type
- Private
- Founded year
- 2016
- Headcount range
- 11–50 employees
- Short description
- GeneCast is a South Korea-based clinical diagnostics company founded in 2016 that develops proprietary ADPS liquid biopsy assays for early detection and mutation analysis of cancer-related genes, serving clinicians, hospitals, and reference laboratories.
- Ownership category
- akta.pro rank
GeneCast industry classification
Industry- Product category
- Liquid Biopsy Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
Keywords
Where GeneCast is headquartered
LocationHeadquarters
- HQ city
- Songpadong
- HQ country
- South Korea
- HQ region
- Asia
Markets served
GeneCast business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
GeneCast product offering
Product offeringCore offering
GeneCast develops liquid biopsy cancer diagnostics using its proprietary ADPS (Advanced Detection of Pivotal Sequences) technology. The company provides early detection and mutation analysis of cancer-related genes through blood-based testing, serving oncology and clinical diagnostic applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Liquid Biopsy Cancer Diagnostics (ADPS-based)
Companies that use GeneCast
Customer profileIdeal customer profiles1 record
GeneCast technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
GeneCast partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
GeneCast competitors and assessment
Company assessmentDirect peers
- Guardant Health: US-based leader in liquid biopsy for oncology, with Guardant360 and Guardant Reveal (MRD). Directly comparable to GeneCast on liquid biopsy ctDNA technology for cancer mutation detection and MRD, though at much larger scale.
- Natera: US-based molecular diagnostics company with a strong oncology liquid biopsy and MRD franchise (Signatera). Comparable to GeneCast in liquid biopsy ctDNA-based oncology testing, with deeper reimbursement coverage in the US.
- Burning Rock Biotech: China-based oncology diagnostics company focused on NGS-based liquid biopsy and tumor profiling. Closely comparable to GeneCast on technology (NGS liquid biopsy for cancer mutations) and regional positioning in APAC.
- Personalis: US-based cancer genomics company with NeXT Personal (MRD) and ImmunoID Next tumor-profiling assays. Comparable to GeneCast on liquid biopsy-based oncology mutation detection and MRD positioning.
Broad incumbents
- Foundation Medicine: Roche subsidiary offering comprehensive genomic profiling of solid tumors via tissue and liquid biopsy (FoundationOne Liquid CDx). Comparable to GeneCast in oncology mutation profiling, but operates as a broad incumbent with FDA-approved comprehensive assays.
- NeoGenomics: US-based oncology-focused clinical laboratory services and IVD company offering liquid biopsy and tumor profiling. Comparable to GeneCast on oncology testing services, though as a much larger, diversified incumbent.
Regional players
- MiRXES: Singapore-based liquid biopsy company developing early-detection cancer tests with regional APAC distribution. Comparable to GeneCast as an Asia-based liquid biopsy competitor in early cancer detection.
- ACT Genomics: Taiwan-based precision oncology company offering NGS-based cancer panel testing and liquid biopsy services across APAC. Comparable to GeneCast as an Asia-based oncology mutation analysis peer.
- Macrogen: Korea-based genomic services and diagnostics company offering NGS-based clinical testing and liquid biopsy services. Directly comparable Korean peer to GeneCast on technology stack and domestic clinical channels.
- GC Genome: Korean molecular diagnostics subsidiary of Green Cross Holdings (an existing GeneCast investor) offering NGS-based cancer and rare-disease testing. Comparable Korean oncology diagnostics peer with hospital channel access.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
GeneCast social profiles
Digital presenceGeneCast financial estimates
Financial estimateRevenue estimate
Valuation estimate
GeneCast leadership team
Management profileNumber of profiles
Profiles1 record
GeneCast funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GeneCast M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GeneCast
What does GeneCast do?
GeneCast develops liquid biopsy cancer diagnostics using its proprietary ADPS (Advanced Detection of Pivotal Sequences) technology. The company provides early detection and mutation analysis of cancer-related genes through blood-based testing, serving oncology and clinical diagnostic applications.
When was GeneCast founded?
GeneCast was founded in 2016. It employs 11 to 50 people.
Where is GeneCast based?
GeneCast is headquartered in Songpadong, South Korea, in the Asia region.
Who are GeneCast's main competitors?
Direct peers on record are Guardant Health, Natera, Burning Rock Biotech and Personalis. Broad incumbents are Foundation Medicine and NeoGenomics. Regional players are MiRXES, ACT Genomics, Macrogen and GC Genome.
Does GeneCast have an API?
No public API is recorded for GeneCast.
What industry is GeneCast in?
GeneCast's product category is Liquid Biopsy Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 325413 and its SIC code is 2835.